DRKS00004455进行中（未招募）2 期
Randomized, double-blind, placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).
EANM Forschungs GmbH/ EANM Research Ltd.0 个研究点目标入组 0 人开始时间: 2012年10月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Histologically confirmed medullary thyroid carcinoma (C-cell thyroid carcinoma)
- •Recurrent or persistent local disease and/or distant metastases not suitable for local curative treatment (surgery or radiation therapy) assessed by Investigator
- •No more than one prior line of systemic therapy (including no more than 1 prior line with a targeted drug, e.g. kinase inhibitor)
- •Best available supportive care to control (endocrine) symptoms according to current standards established for at least 8 weeks before study entry
- •At least one defined lesion in CT or MRI evaluable for RECIST (v1.1), no older than 42 days from planned treatment start, or at least one defined lesion in CT or MRI not evaluable by RECIST in combination with elevated tumour markers with minimum initial levels of 150 pg/ml for calcitonin or 5 x UILN for CEA (e.g., in case of bone metastases)
- •Progression within previous 12 months (according to RECIST 1.1 criteria or tumour marker progression (calcitonin or CEA referred to normal Reference Ranges from Site Lab) can be used as a basis for the assessment of disease progression); tumour marker doubling time must be no longer than 12 months (30) and a minimum initial level of 150 pg/ml for calcitonin or 5 x UILN for CEA, respectively, need to be present. The tumour marker doubling time should be estimated using the calculator at the ATA-website: http://www.thyroid.org/professionals/calculators/CDTC.php
- •Hb > 8g/dl, WBC >3.000 cells/mm³ (ANC > 1.500 cells/mm³), platelets > 100.000 cells/mm³, bilirubin < 2mg/dl, Alanine aminotransaminase (ALT) and Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (referred to normal Reference Ranges from Site Lab)
- •Performance status: WHO = 2; Karnofsky index = 50%
- •Patients should have sufficient renal function, as determined by serum creatinine <1.5 mg/dl and CrCL > 30ml/min
- •PT-INR and PTT < 1.5 x upper limit of normal (referred to normal Reference Ranges from Site Lab) [Patients who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]
- •No acute infections at the time of therapy initiation
- •Staging studies (MRT or CT and Calcitonin or CEA) completed within four weeks of protocol randomisation
- •Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.
- •Women and men of childbearing potential must agree to use adequate contraception (barrier method of birth control)
- •Patient is able to understand the study procedures, voluntarily agrees to participate in the study and has given a signed and dated written informed consent prior to study participation.
排除标准
- •Unresolved toxicity (i.e. neurotoxicity) attributed to any prior therapy higher than NCI-CTCAE (version 4) Grade 2 (excluding cases of alopecia)
- •Patients with history of allergic or hypersensitivity reaction to study drug or placebo or their excipients or with a history of allergic reactions attributed to compounds with similar composition to any of the study drug or placebo.
- •Current participation in another investigational trial
- •Patients with significant cardiovascular disease, such as myocardial infarction < 6 months, unstable coronary artery disease (anginal symptoms at rest), new-onset angina within 3 months before randomization, or chronic heart failure (New York Heart Association grade III or IV)
- •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy other than beta-blockers or digoxin
- •Congenital long QTc syndrome, history of drug induced QTc prolongation, or QTc interval unmeasurable or more than 450 ms
- •Abnormal serum electrolytes such as potassium, magnesium and calcium
- •Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal management
- •Major surgery, open biopsy, or significant traumatic injury within 30 days prior to randomization
- •Non-healing wound, ulcer, or bone fracture
- •Evidence or history of bleeding diathesis or coagulopathy disorder
- •Hemorrhage/bleeding event = Grade 3 within 3 months prior to first dose of study drug
- •Thrombotic or embolic events including transient ischemic attacks within the past 6 months
- •Subjects with symptomatic brain metastases or Subjects with brain metastases under corticosteroid treatment. Previous or concurrent cancer that is distinct in primary site or histology from thyroid cancer within 5 years prior to randomization EXCEPT cervical cancer in situ, treated basal cell carcinoma and superficial bladder tumours [Ta (Non invasive tumour), Tis (Carcinoma in situ) and T1 (Tumour invades lamina propria)]
- •Pregnant or breast-feeding patients
- •Patients with uncontrolled infections
- •Known human immunodeficiency virus (HIV) infection or infection with hepatitis B or C
- •Immunosuppression
- •Subjects with seizure disorder requiring medication (such as steroids or anti¬epileptics)
- •Subjects undergoing renal dialysis
- •Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results
- •Any malabsorption condition
- •Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study
研究者
相似试验
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled Phase II proof-of-concept study of APD515 solution for oromucosal and oral administration for relief of xerostomia in patients with cancer - Phase II PoC study of APD515 v1.2XerostomiaMedDRA version: 14.0Level: LLTClassification code 10048223Term: XerostomiaSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000978-53-DKAcacia Pharma Ltd30
已完成
1 期
A Phase I study of orally inhaled PB01 in healthy male participants following single and repeat administration.ACTRN12615000984594Paranta Biosciences Ltd56
进行中（未招募）
不适用
A study to look at the effectiveness of a medicine called APD515, designed to be applied to the lining inside the mouth, at relieving dryness of the mouthXerostomiaEUCTR2011-000978-53-GBAcacia Pharma Ltd30
进行中（未招募）
不适用
Randomized, placebo-controlled, double-blind Phase 1b/2 study of U3-1287 (AMG 888) in combination with erlotinib in EGFR treatment naïve subjects with advanced non-small cell lung cancer (NSCLC) who have progressed on at least one prior chemotherapy.EUCTR2010-021082-74-ITDAIICHI SANKYO PHARMA DEVELOPMENT210
尚未招募
2 期
Randomised, double-blind, placebo controlled phase II study of the efficacy of Phospha-E biomarkers of inflammation, in patients with metabolic syndrome and mild to moderate hyperlipidemia.Metabolic SyndromeMetabolic and Endocrine - Other metabolic and endocrine disordersACTRN12607000343404Phosphagenics Limited160